Crossmark

Comment on “Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study”

Crossref DOI link: https://doi.org/10.1007/s12072-025-10970-9

Published Online: 2026-01-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Huikang

Xu, Xinjun

Song, Xicheng

Zhang, Yu
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82271146)

National Natural Science Foundation of China (82271147)
License Information

Text and Data Mining valid from 2026-01-03

Version of Record valid from 2026-01-03
More Information

Article History

Received: 24 October 2025

Accepted: 8 November 2025

First Online: 3 January 2026

Declarations

:

: The authors affirm that they possess no financial conflicts of interest or personal connections that might have swayed the research presented in this paper.

Document is current

Any future updates will be listed below